Innovation To Drive Long-Term Survival In China Pharma Market - But What Kind Of Innovation?
This article was originally published in PharmAsia News
Executive Summary
BEIJING - For Big Pharma and domestic players competing in China's market, innovation is essential for long-term survival, even as pricing strategies might help grab market share over the shorter term, according to a prominent analyst who monitors China's healthcare sector
You may also be interested in...
China Should Step Up Funding For Rural Health Facilities, Medical Devices In New Five-Year Plan - EU Chamber Of Commerce In China
BEIJING - China's new Five Year Plan for economic and social development should be amended to provide greater support for upgrading rural hospitals, physician education, and decades-old medical equipment, according to an assessment of the guidelines by the European Union Chamber of Commerce in China
China Should Step Up Funding For Rural Health Facilities, Medical Devices In New Five-Year Plan - EU Chamber Of Commerce In China
BEIJING - China's new Five Year Plan for economic and social development should be amended to provide greater support for upgrading rural hospitals, physician education, and decades-old medical equipment, according to an assessment of the guidelines by the European Union Chamber of Commerce in China
Reimbursement Expansion To Fuel China Pharma Growth In 2011 (Part 1 of 2)
HONG KONG - China's pharmaceutical market is expected to grow around 26% in the coming year with much of the growth fueled by continued implementation of the government's Essential Drug List (EDL) and reimbursement expansion via government insurance plans, said Katherine Lu, senior analyst for China healthcare at Oppenheimer & Co